Recruiting

Blood and tumor markers to predict immunotherapy success in lung and esophageal cancer

Plain-English translation of NCT06790797 on ClinicalTrials.gov ↗ · Source last updated January 2025 · Translation generated June 2026 · How we translate trials

Read our Lung Cancer research guide →

What is this trial?

Researchers are studying biological markers—special signs in your blood and tumor tissue—that might predict whether PD-1/PD-L1 antibody immunotherapy will work well for you. This study will collect samples before and after you receive this treatment and analyze them using advanced laboratory techniques to understand which immune cells in your body are most important for fighting your cancer.

Currently, doctors cannot easily predict which patients will benefit most from immunotherapy before treatment begins. By identifying biological markers that show how well your immune system is responding, this research could help doctors in the future choose the best treatments for each patient and predict outcomes earlier.

Do you qualify?

You likely qualify if…

you have been diagnosed with lung cancer or esophageal cancer and have agreed to receive PD-1/PD-L1 antibody immunotherapy
you are between 18 and 80 years old
you are in good enough health to participate (ECOG performance status of 0 or 1)
you have normal organ and bone marrow function
your doctors expect you to survive at least 12 weeks
you are willing and able to provide written consent

You likely don't qualify if…

you have an active blood-borne infection such as HIV, hepatitis B, or hepatitis C
you have a blood clotting disorder or are currently taking blood-thinning medications
you have severe psychiatric or mental health conditions that would affect participation
you have poor blood vessel access or a cancer emergency requiring immediate treatment
you have difficulty communicating or cannot commit to long-term follow-up

What participation looks like

You would provide blood samples and allow researchers to study tissue from your tumor surgery using advanced laboratory techniques. Samples would be collected before you start immunotherapy and again after treatment to track changes in your immune cells. The study lasts at least 12 weeks, and you'll need to be available for follow-up appointments so researchers can compare your biological markers with how well the treatment worked for you.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(1 site)

China

The first affiliated hospital of soochow university, Suzhou, Jiangsu